Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy

Varování

Publikace nespadá pod Lékařskou fakultu, ale pod Přírodovědeckou fakultu. Oficiální stránka publikace je na webu muni.cz.

Autoři	DAILLERE Romain DEROSA Lisa BONVALET Melodie SEGATA Nicola ROUTY Bertrand GARIBOLDI Manuela BUDINSKÁ Eva DE VRIES I. Jolanda M. NACCARATI Alessio Gordon ZITVOGEL Valerie CALDAS Carlos ENGSTRAND Lars LOILBL Sibylle FIESCHI Jacques HEINZERLING Lucie KROEMER Guido ZITVOGEL Laurence
Rok publikování	2020
Druh	Článek v odborném periodiku
Časopis / Zdroj	Oncoimmunology
Fakulta / Pracoviště MU	Přírodovědecká fakulta
Citace
www	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466862/
Doi	http://dx.doi.org/10.1080/2162402X.2020.1774298
Klíčová slova	Gut microbiota; anticancer therapeutics; clinical trials
Přiložené soubory	1680256.pdf
Popis	Accumulating evidence demonstrates the decisive role of the gut microbiota in determining the effectiveness of anticancer therapeutics such as immunogenic chemotherapy or immune checkpoint blockade in preclinical tumor models, as well as in cancer patients. In synthesis, it appears that a normal intestinal microbiota supports therapeutic anticancer responses, while a dysbiotic microbiota that lacks immunostimulatory bacteria or contains overabundant immunosuppressive species causes treatment failure. These findings have led to the design of clinical trials that evaluate the capacity of modulation of the gut microbiota to synergize with treatment and hence limit tumor progression. Along the lines of this Trial Watch, we discuss the rationale for harnessing the gut microbiome in support of cancer therapy and the progress of recent clinical trials testing this new therapeutic paradigm in cancer patients.